Avalo Therapeutics (AVTX) Operating Expenses (2014 - 2026)

Avalo Therapeutics' Operating Expenses history runs 13 years deep, the most recent figure standing at $20.9 million for Q1 2026.

• Quarterly Operating Expenses rose 42.48% year-over-year to $20.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $79.2 million (up 55.76% YoY) and the FY2025 annual result came in at $73.0 million, up 5.85% from the prior year.
• Operating Expenses was $20.9 million for Q1 2026 at Avalo Therapeutics, up from $19.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $32.8 million in Q1 2024 and bottomed at $4.0 million in Q3 2023.
• A 5-year average of $14.6 million and a median of $13.1 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses slumped 63.28% — and 2024, when it surged 253.59%.
• Avalo Therapeutics' Operating Expenses stood at $9.8 million in 2022, then fell by 15.61% to $8.2 million in 2023, then jumped by 64.09% to $13.5 million in 2024, then soared by 46.64% to $19.8 million in 2025, then advanced by 5.56% to $20.9 million in 2026.
• Business Quant data shows AVTX's Operating Expenses at $20.9 million in Q1 2026, $19.8 million in Q4 2025, and $19.2 million in Q3 2025.